Cure My Disease

Don't miss your cure!

 Log in / Sign up

New IV drug shows promise for stiff spine disease

NCT ID NCT02186873

Completed Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial tested golimumab, an anti-inflammatory biologic, given as an IV infusion to 208 people with active ankylosing spondylitis. Participants received either golimumab or a placebo. The main goal was to see if more people on golimumab had at least a 20% improvement in symptoms by week 16. The study is complete and aimed at finding a new option for those not helped by standard anti-inflammatory drugs.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
golimumab (a biologic drug given as an intravenous infusion)
What this could lead to
If successful, this could provide a new treatment option for people with active ankylosing spondylitis who haven't responded to standard anti-inflammatory drugs.
What could go wrong
This is a completed Phase 3 trial, but results may not apply to all patients. As an immune-suppressing drug, golimumab carries risks like serious infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANKYLOSING SPONDYLITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ankylosing spondylitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANKYLOSING SPONDYLITIS

Contacts and locations

Locations

  • Study site

    Glendale, Arizona, United States

  • Study site

    Mesa, Arizona, United States

  • Study site

    La Palma, California, United States

  • Study site

    Granger, Indiana, United States

  • Study site

    St Louis, Missouri, United States

  • Study site

    Orchard Park, New York, United States

  • Study site

    Salisbury, North Carolina, United States

  • Study site

    Middleburg Heights, Ohio, United States

  • Study site

    Duncansville, Pennsylvania, United States

  • Study site

    Austin, Texas, United States

  • Study site

    Houston, Texas, United States

  • Study site

    Maroochydore, Australia

  • Study site

    St. John's, Newfoundland and Labrador, Canada

  • Study site

    Burlington, Canada

  • Study site

    Trois-Rivières, Canada

  • Study site

    Bad Doberan, Germany

  • Study site

    Berlin, Germany

  • Study site

    Erfurt, Germany

  • Study site

    Hamburg, Germany

  • Study site

    Planegg, Germany

  • Study site

    Ratingen, Germany

  • Study site

    Zerbst, Germany

  • Study site

    Chihuahua City, Mexico

  • Study site

    Bydgoszcz, Poland

  • Study site

    Bytom, Poland

  • Study site

    Nadarzyn, Poland

  • Study site

    Nowa Sól, Poland

  • Study site

    Poznan, Poland

  • Study site

    Warsaw, Poland

  • Study site

    Moscow, Russia

  • Study site

    Saint Petersburg, Russia

  • Study site

    Saratov, Russia

  • Study site

    Smolensk, Russia

  • Study site

    Tver', Russia

  • Study site

    Ansan, South Korea

  • Study site

    Daegu, South Korea

  • Study site

    Gwangju, South Korea

  • Study site

    Seongdong-Gu, South Korea

  • Study site

    Seoul, South Korea

  • Study site

    Chernihiv, Ukraine

  • Study site

    Dnipropetrovsk, Ukraine

  • Study site

    Kyiv, Ukraine

  • Study site

    Odesa, Ukraine

  • Study site

    Vinnytsia, Ukraine

  • Study site

    Zaporizhzhia, Ukraine

More trials for these conditions

Other studies related to the condition(s) this trial covers.